Immix Biopharma (IMMX) Change in Cash (2021 - 2026)

Immix Biopharma has reported Change in Cash for 6 years, with the latest figure at -$14.7 million in Q1 2026.

• Quarterly Change in Cash fell 733.6% year-over-year to -$14.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.3 million (up 572.67% YoY) and the FY2025 annual result came in at $76.2 million, up 44187.46% from the prior year.
• Change in Cash slipped to -$14.7 million in Q1 2026 per IMMX's latest filing, from $78.0 million in the prior quarter.
• Over five years, Change in Cash peaked at $78.0 million in Q4 2025 and troughed at -$14.7 million in Q1 2026.
• A 5-year average of $3.6 million and a median of -$1.8 million in 2025 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2022 and 2025: Change in Cash plunged 1946.43% in 2022, then soared 3982.61% in 2025.
• Over 5 years, Change in Cash stood at -$3.5 million in 2022, then surged by 40.44% to -$2.1 million in 2023, then grew by 3.1% to -$2.0 million in 2024, then jumped by 3982.61% to $78.0 million in 2025, then slumped by 118.82% to -$14.7 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$14.7 million, $78.0 million, and $4.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.